Cordlife’s Loss Narrows, but Cash Flow and Unresolved Claims Keep Dividends on Hold

Cordlife Group (SGX: P8A) reported a smaller loss for the nine months ended 30 September 2026, but the improvement has not brought back a dividend. In its unaudited results announced on 13 November, the company said directors declared or recommended no payout for the period. They cited uncertainty over ongoing investigations, legal proceedings and further testing of cord blood storage tanks. [S1, p. 3] [S1, p. 35] [S1, p. 45] [S1, p. 47]

For a dividend investor, the question is whether lower costs are becoming a durable recovery in earnings and cash generation. The latest figures give a mixed answer.

Costs fell, but so did revenue

Nine-month revenue declined to S$25.18 million from S$29.39 million a year earlier. The group’s net loss narrowed to S$5.79 million from S$7.08 million, helped by lower selling, marketing and administrative expenses. Cordlife attributed part of the spending reduction to reduced marketing activity in Singapore while new cord blood collections remain suspended there. Lower spending therefore does not, by itself, show that the core business has recovered. [S1, p. 3] [S1, p. 39] [S1, p. 40]

The latest quarter was weaker than the nine-month comparison suggests. Revenue for the three months to September fell to S$7.89 million from S$10.21 million, while the quarterly net loss widened to S$3.13 million from S$2.48 million. That makes the next results important for judging whether cost savings can continue to offset lost sales. [S1, p. 3]

Cash generation has yet to recover

Net cash from operating activities was an outflow of S$263,000 for the nine months, compared with an inflow of S$795,000 a year earlier. The current figure already includes S$3.43 million of interest received. Before working-capital movements, operating cash flow was negative S$3.53 million. These are different measures, but together they show why a narrower accounting loss is not yet clear evidence of cash available for dividends. [S1, p. 8]

Cordlife reported S$57.3 million across group cash, fixed deposits and short-term investments at 30 September, down from S$61.0 million at the previous year-end. That pool offers financial flexibility, but it should not be read as a dividend commitment: the group still faces operating outflows and uncertain obligations. [S1, p. 41] [S1, p. 19] [S1, p. 20]

What stands between Cordlife and a payout?

Cordlife’s Singapore licence was renewed in January 2026 with conditions that continue to restrict new cord blood collections. The filing also says the outcome and financial effect of customer claims, regulatory investigations and testing involving three other tanks remain uncertain. Its auditors had issued a disclaimer of opinion on the 2025 annual statements, including over going concern, refunds and claims, and receivable valuations. The current interim figures have not been audited or reviewed. [S1, p. 18] [S1, p. 31] [S1, p. 32] [S1, p. 35]

The board says it will review dividends at the financial year-end, taking performance and business plans into account. For now, the answer is clear: the smaller nine-month loss did not lead to a payout. Investors watching for a change need evidence that collections can resume, cash generation can recover and the unresolved claims can be assessed more firmly. [S1, p. 45] [S1, p. 8] [S1, p. 18]